VCEL Vericel Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 887359 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY25.3%
TTM net income YoY154.6%
TTM EPS YoY146.2%
Revenue 3-yr CAGR20.5%
Net income 3-yr CAGR—
Margins
Gross margin74.5%
Operating margin8.3%
Net margin10.3%
FCF margin17.9%
EBITDA margin12.4%
Returns
ROE9.4%
ROA6.9%
ROIC (approx.)9.0%
Asset turnover0.67x
Leverage & solvency
Liabilities / assets25.7%
Debt / equity0.00x
Current ratio5.13x
Interest coverage42.01x
Cash quality & payout
Operating cash flow / net income1.96x
Accruals ratio-6.6%
Payout ratio—
Capex / revenue2.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $85.37M | $77.46M | $68.42M | $92.92M | $67.50M | $63.24M | $52.60M | $75.38M |
| Cost of revenue | $22.76M | $21.05M | $19.16M | $19.79M | $17.92M | $16.63M | $16.32M | $16.88M |
| Gross profit | $62.61M | $56.40M | $49.27M | $73.13M | $49.59M | $46.61M | $36.27M | $58.50M |
| R&D expense | $6.88M | $7.49M | $8.10M | $7.25M | $6.32M | $6.73M | $7.26M | $4.92M |
| SG&A expense | $43.54M | $48.48M | $49.23M | $43.46M | $39.82M | $41.91M | $41.80M | $35.10M |
| Operating income | $12.19M | $434,000 | -$8.06M | $22.41M | $3.45M | -$2.03M | -$12.79M | $18.48M |
| Interest expense | $160,000 | $160,000 | $160,000 | $162,000 | $158,000 | $157,000 | $153,000 | $154,000 |
| Pretax income | — | — | — | — | — | — | — | $19.95M |
| Income tax | — | — | — | — | — | — | — | $148,000 |
| Net income | $14.16M | $2.21M | -$6.30M | $23.24M | $5.07M | -$553,000 | -$11.25M | $19.81M |
| EBITDA | $15.69M | $3.93M | -$4.80M | $25.50M | $6.25M | $671,000 | -$10.11M | $19.96M |
| EPS (basic) | 0.28 | 0.04 | -0.12 | — | 0.10 | -0.01 | -0.23 | — |
| EPS (diluted) | 0.27 | 0.04 | -0.12 | — | 0.10 | -0.01 | -0.23 | — |
| Weighted avg. shares (diluted) | 52.96M | 52.31M | 50.77M | — | 51.91M | 50.37M | 49.91M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $133.49M | $125.36M | $109.30M | $100.09M | $100.40M | $80.53M | $73.49M | $85.05M |
| Short-term investments | $36.77M | $37.10M | $36.05M | $37.41M | $34.98M | $36.35M | $39.41M | $41.69M |
| Receivables | $81.80M | $75.71M | $72.38M | $84.63M | $60.43M | $64.29M | $52.90M | $61.38M |
| Inventory | $17.06M | $18.38M | $18.35M | $17.56M | $18.16M | $16.83M | $17.11M | $17.37M |
| Current assets | $280.77M | $264.73M | $244.06M | $247.44M | $221.97M | $204.58M | $197.64M | $212.78M |
| PP&E, net | $105.08M | $105.60M | $107.11M | $108.40M | $109.38M | $109.85M | $108.29M | $103.16M |
| Intangibles | $5.16M | $5.31M | $5.47M | $5.62M | $5.78M | $5.94M | $6.09M | $6.25M |
| Total assets | $517.11M | $502.87M | $485.63M | $487.97M | $453.27M | $435.61M | $424.59M | $432.72M |
| Current liabilities | $54.72M | $52.53M | $47.16M | $49.15M | $45.58M | $41.13M | $39.45M | $50.29M |
| Total liabilities | $132.94M | $132.82M | $129.40M | $133.33M | $131.42M | $128.80M | $129.10M | $140.75M |
| Shareholders' equity | $384.17M | $370.04M | $356.23M | $354.64M | $321.86M | $306.81M | $295.49M | $291.97M |
| Shares outstanding | 51.04M | 51.17M | 51.01M | 50.62M | 50.55M | 50.44M | 50.25M | 49.63M |
| Cash flow statement | ||||||||
| Operating cash flow | $17.72M | $16.19M | $16.38M | $15.01M | $22.08M | $8.21M | $6.60M | $22.24M |
| Capital expenditure | $2.04M | $1.93M | $1.26M | $2.19M | $2.63M | $8.13M | $14.21M | $13.79M |
| Free cash flow | $15.68M | $14.26M | $15.13M | $12.83M | $19.45M | $81,000 | -$7.61M | $8.46M |
| Investing cash flow | -$2.71M | -$2.82M | -$4.20M | -$16.39M | -$3.38M | -$9.03M | -$15.14M | -$14.65M |
| Financing cash flow | -$6.88M | $2.69M | -$2.98M | $1.06M | $1.17M | $1.64M | $3.20M | $7.11M |
| Depreciation & amortization | $3.50M | $3.50M | $3.27M | $3.09M | $2.80M | $2.70M | $2.69M | $1.48M |
| Stock-based compensation | $7.82M | $9.08M | $11.29M | $8.42M | $8.70M | $10.14M | $11.51M | $7.92M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.